The introduction of immune checkpoint inhibitors has greatly revolutionized the overall paradigm of cancer therapy. Immune checkpoint inhibitors have shown encouraging response in the management of several malignancies including melanoma, non-small cell lung cancer, bladder cancer, urothelial cancer, and others.
Global Immune Checkpoint Inhibitors Biomarkers & Clinical Trials Insight 2028 Report Highlights:
- Global Immune Checkpoint Inhibitors Market Opportunity: > USD 30 Billion
- Immune Checkpoint Inhibitors Clinical Trials Insight: CTLA-4, LAG3, PD-1/PD-L1, TIGIT Inhibitors
- Immune Checkpoint Inhibitors Clinical Trials Insight: > 300 Drugs In Trials
- Biomarkers sourced During clinical Trials
- Biomarkers Insight By Immune Checkpoint Inhibitors Classification
- Insight On Biomarkers Sourced From Trials By Drugs & Indication
- Biomarker Name & Function Insight By Immune Checkpoint Inhibitor Drug
- Biomarker Insight Based On Drugs In Multiple Trials Phase & Multiple Indication
Download Report:
https://www.kuickresearch.com/report-immune-checkpoint-inhibitors-biomarkers
The introduction of immune checkpoint inhibitors has greatly revolutionized the overall paradigm of cancer therapy. Immune checkpoint inhibitors have shown encouraging response in the management of several malignancies including melanoma, non-small cell lung cancer, bladder cancer, urothelial cancer, and others. However, despite the breakthrough in the development of immune checkpoint inhibitors, some patients do not response to the therapy and develop drug resistance. This has surged the identification and development of predictive biomarkers to determine the efficacy of immune checkpoint inhibitors.
The cancer biomarker market has recently gained momentum and is highly competitive. To strengthen their position in the market, the key players are focusing on the introduction of novel biomarker tests, and mergers and acquisitions with other prominent companies to maintain strong global presence. For instance, Leica Biosystems has entered into an agreement with Leap Therapeutics to develop a companion diagnostic to detect Dickkopf-related protein 1 (DKK1). The assay will be used to support clinical development of Leap Therapeutics’ anti-DKK1 cancer therapy, DKN-01, currently being studied in clinical trials. Furthermore, EpiSwitch CIRT developed by Oxford BioDynamics has also gained approval from US FDA. The first-of-its-kind clinical blood test predicts the likelihood of a cancer patient’s response to immune checkpoint inhibitors including anti-PD-L1 and anti-PD-1 immunotherapies.
Currently, more than 300 clinical trials are ongoing which are evaluating the role of biomarkers in cancer patients. These trials are rapidly identifying novel biomarkers which have the potential to enter the market during the forecast period. For instance, a recent study suggests that immune cell related parameters can serve as biomarker for response to Nivolumab/Ipilimumab in clear cell renal cell carcinoma. Further, researchers have also identified several blood biomarkers which can help to predict the response of immune checkpoint inhibitors in melanoma. The circulating immune cells of patients who responded to immune checkpoint inhibitor treatment had an increased extracellular acidification rate. Investigators also found changes in mitochondrial shape and structure changes that were linked to response.
The major key players in the market include Roche, Abbot Laboratories, Bristol Myers Squibb, GlaxoSmithKline, Novartis, Illuminia, Thermo Fisher Scientific, Eli Lilly, and others. Our report provides comprehensive analysis on the approved biomarkers for cancer immune checkpoint inhibitors. Apart from this, in-depth analysis on the ongoing clinical trials in biomarkers associated with immune checkpoint inhibitor therapy by various phases and therapeutic indications is also mentioned in the report.
Although the prevalence of cancer is increasing globally and growing number of patients require diagnostic tests, lack of reimbursement policies for biomarker tests in the emerging regions is one of the major factor restraining the growth of market during the forecast period. Another major restraining factor for the growth of market is the high cost for diagnosis and treatment of cancer. This is also limiting the number of patients undergoing biomarker testing, and growing preference of patients towards the other low cost-detecting tests. However, the advancement in the field of biotechnology will ultimately lower the cost of biomarker test in coming years, which will drive the market during the forecast period.
As per our report findings, the global immune checkpoint inhibitor biomarker market is expected to surpass US$ 25 Billion by 2028. The increasing prevalence of cancer is a key factor propelling the growth of the market during the forecast period. Furthermore, the market is also witnessing a significant rise on account of the growing demand for drug discovery and development for various cancer types. In addition to this, several pharmaceutical giants are investing massive amounts into research and development of novel biomarkers for cancer therapeutics. Moreover, many clinical trials and pipeline studies are currently heading towards the end stages of development, and their market entry is likely to attract high cancer biomarkers market revenue during the forecast period.
Contact:
Neeraj Chawla
Kuick research
Research Head
+91-981410366
neeraj@kuickresearch.com
https://www.kuickresearch.com